| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42001190 | EBV | ENSG00000067225.21 | protein_coding | PKM | No | No | 5315 | B4DNK4 P14618 |
| TVIS10000226 | HBV | ENSG00000067225.21 | protein_coding | PKM | No | No | 5315 | B4DNK4 P14618 |
| TVIS10000227 | HBV | ENSG00000067225.21 | protein_coding | PKM | No | No | 5315 | B4DNK4 P14618 |
| TVIS30038850 | HIV | ENSG00000067225.21 | protein_coding | PKM | No | No | 5315 | B4DNK4 P14618 |
| TVIS44009276 | HTLV-1 | ENSG00000067225.21 | protein_coding | PKM | No | No | 5315 | B4DNK4 P14618 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PKM |
|---|---|
| DrugBank ID | DB00119 |
| Drug Name | Pyruvic acid |
| Target ID | BE0000088 |
| UniProt ID | P14618 |
| Regulation Type | |
| PubMed IDs | 16132722; 17308100; 16741870; 17587357; 16375581 |
| Citations | Li Y, Chang Y, Zhang L, Feng Q, Liu Z, Zhang Y, Zuo J, Meng Y, Fang F: High glucose upregulates pantothenate kinase 4 (PanK4) and thus affects M2-type pyruvate kinase (Pkm2). Mol Cell Biochem. 2005 Sep;277(1-2):117-25.@@Stetak A, Veress R, Ovadi J, Csermely P, Keri G, Ullrich A: Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res. 2007 Feb 15;67(4):1602-8.@@Vlaeminck-Guillem V, Safi R, Guillem P, Leteurtre E, Duterque-Coquillaud M, Laudet V: Thyroid hormone receptor expression in the obligatory paedomorphic salamander Necturus maculosus. Int J Dev Biol. 2006;50(6):553-60.@@Weinberger R, Appel B, Stein A, Metz Y, Neheman A, Barak M: The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma. Eur J Cancer Care (Engl). 2007 Jul;16(4):333-7.@@Staib P, Hoffmann M, Schinkothe T: Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors. Clin Chem Lab Med. 2006;44(1):28-31. |
| Groups | Approved; Investigational; Nutraceutical |
| Direct Classification | Alpha-keto acids and derivatives |
| SMILES | CC(=O)C(O)=O |
| Pathways | Citrullinemia Type I; 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency; Glycogenosis, Type IB; Argininemia; Pyruvate Kinase Deficiency; Pyruvate Carboxylase Deficiency; Amino Sugar Metabolism; The Oncogenic Action of Fumarate; 3-Phosphoglycerate Dehydrogenase Deficiency; Glycolysis; Non-Ketotic Hyperglycinemia; 2-Hydroxyglutric Aciduria (D and L Form); Glucose-Alanine Cycle; G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease; Alanine Metabolism; Hyperglycinemia, Non-Ketotic; Cystinosis, Ocular Nonnephropathic; Dimethylglycine Dehydrogenase Deficiency; Glycogenosis, Type VII. Tarui Disease; Dihydropyrimidine Dehydrogenase Deficiency (DHPD); Lactic Acidemia; Homocarnosinosis; Primary Hyperoxaluria Type I; Ornithine Transcarbamylase Deficiency (OTC Deficiency); The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxygluaricaciduria; Sarcosinemia; Urea Cycle; Phosphoenolpyruvate Carboxykinase Deficiency 1 (PEPCK1); Cysteine Metabolism |
| PharmGKB | PA164778686 |
| ChEMBL | CHEMBL1162144 |
